PD-L1 CPS ist ein kontinuierlicher IHC-Score, der als Förderschwelle für ICI-haltige...

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

ID	`BMA-PDL1-CPS-GASTRIC`
Art	Therapeutische Relevanz
Status	reviewed 2026-05-07 \| actionability review required
Erkrankungen	`DIS-GASTRIC`
Quellen	`SRC-CHECKMATE-649-JANJIGIAN-2022` `SRC-ESMO-GASTRIC-2024` `SRC-NCCN-GASTRIC-2025`

Fakten zur Handlungsfähigkeit

Biomarker	`BIO-PDL1-CPS`
Erkrankung	`DIS-GASTRIC`
ESCAT-Stufe	IA
Empfohlene Kombinationen	nivolumab + fluoropyrimidine + platinum (CPS≥5, 1L per SRC-NCCN-GASTRIC-2025, SRC-ESMO-GASTRIC-2024), nivolumab + FOLFOX/XELOX (CPS≥1 broader population per SRC-CHECKMATE-649-JANJIGIAN-2022)
Zusammenfassung der Beweise	PD-L1 CPS is a continuous IHC score used as an eligibility threshold for ICI-containing regimens in metastatic gastric/GEJ adenocarcinoma. Thresholds vary by regimen: CPS ≥5 — nivolumab + fluoropyrimidine + platinum (CheckMate-649; mOS 14.4 vs 11.1 mo, HR 0.71 in CPS≥5 subgroup); CPS ≥1 — nivolumab + chemo as broader population (CM-649); CPS ≥1 — pembrolizumab + trastuzumab + chemo for HER2+ disease (KEYNOTE-811, covered separately in BMA-HER2-AMP-GASTRIC). Per NCCN and ESMO 2024, PD-L1 CPS testing by IHC 22C3 pharmDx is mandatory prior to 1L treatment selection. Threshold-gated indication selection is performed by the algorithm layer (IND-GASTRIC-METASTATIC-1L-PDL1-CHEMO-ICI); this BMA entry surfaces ESCAT tier context for tumor-board discussion only.

Anmerkungen

Variant_qualifier is null (gene-level) — CPS is a continuous score; specific threshold gating (CPS≥5 vs ≥1) is enforced by the indication layer, not this BMA cell. This entry exists to prevent the render layer from showing "Not in KB" for a well-defined, FDA-approved biomarker. KEYNOTE-811 evidence is attributable to BMA-HER2-AMP-GASTRIC to avoid overlap.

Verwendet von

Keine Rückverweise im YAML-Korpus gefunden.